We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $469 invested in Navidea Biopharmaceuticals Inc. in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% less funds holding

Funds holding: 24 → 4 (-20)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 21

100% less capital invested

Capital invested by funds: $226K → $469 (-$225K)

Holders
4
Holders Change
-20
Holders Change %
-83.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baader Bank Aktiengesellschaft
Germany
+$892
2
ASN
Advisory Services Network
Georgia
+$21

Top Sellers

Rank Fund Capital Flow
1
ACM
Allred Capital Management
Texas
-$41.9K
2
State Street
State Street
Massachusetts
-$37K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$33.1K
4
VF
Virtu Financial
New York
-$30K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$24.8K

NAVB Hedge Fund Activity: Q4 2023 in Review

4 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2023, worth a combined $469 — down 100% from $226K a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of NAVB and 2 opened new positions — a net loss of 19 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $892. The largest seller was Allred Capital Management, exiting entirely with an estimated $41.9K sold.

  • 4 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2023, down from 24 in Q3 2023.
  • Funds reported $469 of Navidea Biopharmaceuticals Inc. stock for Q4 2023, down 100% quarter-over-quarter.
  • 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2023 and 21 closed out, a net change of -19 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2023 was Baader Bank Aktiengesellschaft, an estimated $892 added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2023 was Allred Capital Management, an estimated $41.9K sold.

Based on aggregated 13F filings for Q4 2023.